by admin | Jul 29, 2022 | Press Releases
Basel, 29 July 2022 – Anaveon today announced that it will present new clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as new pre-clinical data further elucidating the mode of action of this powerful and selective... 
by admin | Jul 13, 2022 | Press Releases
Dr Phillips brings 30 years of healthcare leadership experience in commercial operations, business strategy, business development and drug development functions. 
by admin | Jul 13, 2022 | Press Releases
Anaveon, a clinical-stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND application for ANV419-101, a Phase I/II mono treatment dose confirmation and combination dose-finding, global study, in patients with advanced cutaneous melanoma. 
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual MeetingMarch 23, 2023
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myelomaMarch 16, 2023
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanomaFebruary 2, 2023